12 March 2018 - - According to a new report published by Albany, New York-based global market intelligence company Transparency Market Research (TMR), the surge in incidences of hypertension and hyperlipidemia is likely to spur the demand of cardiovascular drugs in the coming years (2017 to 2025), the company said.
The global cardiovascular drugs market was valued at approximately USD 80bn in 2016 is projected to register cumulative annual growth rate of over 1.0% from 2017 to 2025.
As key players introduce their new cardiovascular drugs in developed markets such a North America and Western Europe, these regions are likely to account for dominating share of the global cardiovascular drugs market.
Changing dietary habits and sedentary lifestyle trends in emerging markets such as China and India is likely to boost growth of Asia Pacific cardiovascular drugs market at a CAGR of around 2.0% from 2017 to 2025.
The report offers detailed segmentation of global cardiovascular drugs market based on drug class, indication and distribution channel. Among the drug class studied, anti-clotting agents segment is poised to account for leading share of the global market during the forecast period from 2017 to 2025.
Meanwhile, the renin-angiotensin system blockers (ARBs) segment is anticipated to lose its market share during the forecast period, and is expected to hold a share of ~16.0% by 2025 from ~18.0% in 2016. Availability of generics and adverse effects associated with ACE inhibitors and ARBs are factors likely to hamper this segment.
Among indications, hypertension segment is projected to hold dominant share of global cardiovascular drugs market during the forecast period and is likely to expand at CAGR of around 1.5% from 2017 to 2025.
The arrhythmia segment, which accounted for a meager share of global cardiovascular drugs market, is anticipated to have substantial growth and account for approximately 4.0% of market share by 2025. Advancements in implantable cardiovascular devices and battery free pacemakers to treat arrhythmia is likely to hamper the arrhythmia drugs market.
Key Players such as AstraZeneca, Bayer AG, and Merck and Co., Inc. are likely to continue to lead the global cardiovascular drugs market.
TMR provides business information reports and services. Its team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.
The company's data repository is continuously updated and revised by a team of research experts to reflect the latest trends and information, and it employs rigorous primary and secondary research techniques to develop distinctive data sets and research material for business reports.